These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2015-005758-36||A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chroni...||not-yet-due|
|Other||2016-004339-19||A Multi-Center, Open-Label, Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304||not-yet-due|
|Other||2016-004718-90||A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk...||not-yet-due|
|Listed as ongoing, but also has a completion date||2017-000638-75||Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)||2020-11-06||bad-data|
|Listed as ongoing, but also has a completion date||2017-000639-15||Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)||2020-11-12||bad-data|
|Ongoing||2019-003625-16||An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Otvoreni nastavak kliničkog ispitivanja Ublituximaba u ispitanika s relapsnom multiplom sklerozom||not-yet-due|